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Objectives: Upon completion of this article, the reader will be
able to describe the use of PET/CT in the evaluation of patients
before, during, and after percutaneous ablation of
malignancies.
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New York. TUSM is accredited by the ACCME to provide
continuing medical education for physicians.
Credit: Tufts University School of Medicine designates this
journal-based CME activity for a maximum of 1 AMA PRA
Category 1 Credit™. Physicians should claim only the credit
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activity.
Percutaneous thermal ablation is a potentially curative
treatment option for patients with one to several small
primary malignancies or metastatic lesions in the lungs or
liver. Advantages over surgical resection include decreased
morbidity, lower complication rates, and decreased hospital
expenses associated with predominately same-day proce-
dures. Positron emission tomography/computed tomography
(PET/CT) provides both metabolic and anatomic information
and is useful initially for disease staging to determine if
percutaneous ablation should be performed, periprocedur-
ally for lesion targeting, and postprocedurally to evaluate for
residual disease and/or recurrence. In this article, the authors
review the use of PET/CT imaging before, during, and after
percutaneous ablation of hepatic and pulmonary primary and
secondary malignancies. In addition, several new applica-
tions of PET for patients undergoing ablation that could
become widely used after further research are discussed.
PET/CT before Percutaneous Tumor Ablation
Hepatic Malignancies
Percutaneous ablation of hepatic malignancies is typically
indicated for patients with three or fewer lesions measuring
no greater than 3 cm each, without evidence of intravascular
or extrahepatic disease.1 PET/CT has been shown to be
superior to CT or magnetic resonance imaging (MRI) alone
in staging patientswith hepaticmetastases and can often lead
to a change in the treatment plan in patients being considered









Abstract The combination of anatomic and metabolic information provided by positron emission
tomography (PET)/computed tomography makes it an important imaging modality to
be obtained in conjunction with percutaneous ablation of primary and secondary
malignancies of the lungs and liver. Advantages include more accurate preprocedural
staging to determine appropriate treatment options, intraprocedural guidance to target
difficult-to-see lesions, and postprocedural detection of residual or recurrent disease.
Future applications of PET include strategies for intraprocedural guidance with real-time
determination of incompletely ablated tumor, and combined PET/magnetic resonance
imaging before, during, and after ablation for greater sensitivity to detect disease.
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PET/CT in 58 patients before radiofrequency ablation (RFA) of
hepatic tumors, and reported an accuracy of 98% in the
identification of extrahepatic disease.2 Preablation PET/CT
led to a change in clinical management in 26% (15/58) of
patients in whom extrahepatic disease was identified and
ablation was not performed. Similarly, Georgakopoulos et al
found that PET/CT altered the clinical management in 25%
(4/16) of potential RFA candidates with colorectal hepatic
metastases in whom extrahepatic disease missed by conven-
tional imaging, and systemic chemotherapy was offered
instead of performing ablation.3
Pulmonary Malignancies
PET/CT imaging is also useful before percutaneous ablation
for staging patients with primary or metastatic lung tumors.
In a prospective study of patientswith colorectal cancer being
considered for ablation of pulmonary metastases, Kodama
et al reported that PET/CT changed the treatment strategy in
20% (12/60) of patients in whom extrapulmonary metastases
missed by whole body CT were identified.4 Ablation was
canceled in 12% (7/60), and the treatment plan was modified
to include additional procedures or chemotherapy following
ablation in another 8% (5/60). PET/CTwas especially valuable
in patients with an elevated serum carcinoembryonic antigen
(CEA) level (> 6 ng/mL); extrapulmonary metastases were
identified in 36% (9/25) compared with 9% (3/35) in patients
with serum CEA levels  6 ng/mL. Deandreis et al also found
that PET/CT before percutaneous ablation of primary and
metastatic pulmonary lesions often led to an alternative
treatment strategy.5 In this study, percutaneous ablation
was canceled in 12% (4/34) of patients, percutaneous ablation
of additional pulmonary lesions was performed in 12% (4/34)
of patients, and percutaneous ablation along with thyroid
surgery was performed in 3% (1/34) of patients.
PET/CT before pulmonary ablation may also be useful for
predicting patients at risk for local recurrence after abla-
tion of pulmonary malignancies (►Fig. 1). Two retrospec-
tive studies found an association between a higher
preablation maximum standard-uptake value (SUV) and a
higher risk of local recurrence.6,7 Harada et al found that
patients with SUVs in the upper third of the study popula-
tion had an odds ratio of recurrence of 4.1 compared with
patients in the lower third.6 Singnurkar et al also deter-
mined that a higher SUV was associated with a greater risk
of local recurrence.7 Both of these studies, however, are
confounded by the association between SUV and tumor
size, which is also independently associated with higher
risk of recurrence after ablation.8
PET/CT during Percutaneous Tumor Ablation
PET/CT is more sensitive than conventional ultrasound (US),
CT, or MRI in the detection of recurrent pulmonary and
hepatic malignancies.9,10 For patients with lesions amenable
to ablation and visible only with PET imaging, PET may be
useful for guiding the placement of ablation probes; a variety
of techniques havebeen described to incorporate PET imaging
into intraprocedural guidance.
PET-guided procedures have been performed in dedicated
PET/CT scanners.11 PET images obtained at the beginning of
the procedure can be fused with intermittent CT images
obtained to guide needle placement. In addition, a method
for directly using PET images for guidance was described
by Prior et al.12 Using this method, a small amount of
18F-fluorodeoxyglucose (FDG) is placed within an introducer
needle allowing visualization of the needle tip using the PET
scanner. PET images are then used to guide the introducer
needle to an FDG avid lesion not visiblewith CTor US imaging.
Challenges with the above method include the availability of
combined PET/CT scanners for procedural use, in addition to
the longer gantries needed for PET imaging that can be
physically cumbersome during attempted needle placement.
PET/CT-guided ablations may also be accomplished by
fusing diagnostic PET images obtained before the procedure
with intraprocedural CT images.13,14 The intraprocedural CT
images may be directly registered to the PET images
or indirectly registered to the CT images from the prior
PET/CT. Fused PET/CT images can allow for more precise
placement of ablation probes to ensure adequate treatment
of difficult-to-see lesions with one treatment, and may po-
tentially reduce the rate of residual/recurrent malignancy.
Figure 1 (A) Axial image from PET acquired 1 day after percutaneous
radiofrequency ablation of NSCLC in the right upper lobe shows
photopenic region centrally with asymmetric activity along the ante-
rior medial border (arrow). (B) Follow-up PET acquired 6 months later
shows significantly increased activity at the ablation site (arrow)
consistent with recurrent disease. NSCLC, non-small-cell lung carci-
noma; PET, positron emission tomography.
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The use of periprocedural PET/CT imaging to determine
ablation completeness has also been investigated, but single
FDG dose imaging has not been found to be helpful. A
prospective study by Sainani et al investigated the use of
FDG PET/CT for guiding percutaneous RFA and cryoablation
with an immediate postprocedural PET/CT to determine if the
preprocedural dose of FDG was dissipated by the ablation
procedure.15 Following ablation, both the tumor SUVmax and
ratio of tumor SUVmax-to-average liver SUV were measured.
No decrease in FDG activity (SUVmax or SUVmax-to-liver ratio)
within the treated lesionswas identified following ablation. A
case report by Schoellnast et al also found that preprocedur-
ally administered FDG within pulmonary tumors were not
dissipated by ablation and could not be used to determine
ablation completeness.16
PET/CT following Percutaneous Tumor
Ablation
Hepatic Malignancies
Unfortunately, recurrence after percutaneous ablation of
hepatic malignancy is relatively common. Following ablation
of hepatocellular carcinoma, local recurrence rates of 11 to
36% have been describedwithmore frequent recurrence after
treatment of larger lesions and lesions close to large vessels.17
Comparedwith hepatocellular carcinoma, metastatic colorec-
tal cancer recurs even more frequently, with rates over 50%
reported.17,18 Therefore, high-quality follow-up imaging is
needed after percutaneous ablation to identify residual or
recurrent neoplasm early enough to retreat while the lesions
remain small. The challenge, however, is to distinguish find-
ings suggestive of recurrent or residual disease from those
present due to normal treatment response.
Immediately following thermal ablation of the liver, the
central area of postablation necrosis is surrounded by a zone
of hyperemiawith blood-filled sinusoids and a peripheral rim
of mild reactive change.19 Early postablation imaging of the
liver with contrast-enhanced MR, CT, and US demonstrates a
rim of increased enhancement compared with normal liver
tissue in the hyperemic zone surrounding the central non-
enhancing area of necrosis (►Fig. 2). The rim of increased
enhancement may mask residual viable tumor in the early
postablation period. Cells destroyed by thermal ablation lose
their ability to concentrate glucose within the cell, and FDG
PET demonstrates a corresponding photopenic area (►Fig. 3).
Glucose metabolism within the zone of hyperemia is unal-
tered and normal FDG uptake or a rim of uniform, low-grade
FDG uptake surrounding the ablation site may be present.
Within the first 48 hours following ablation, focal areas of
increased FDG uptake adjacent to the photopenic area of
necrosis suggest residual macroscopic tumor.20 At 3 days and
lasting up to 6 months following ablation, a band of regener-
ative tissue containing neutrophils and fibroblasts is ob-
served that demonstrates variable degrees of both
peripheral enhancement and increased FDG uptake sur-
rounding the ablation site.19
The combined functional and anatomic information pro-
vided by PET/CT offers advantages over traditional morpho-
logic imaging by US, CT, and MR in distinguishing residual or
recurrent neoplasm from postablation change (►Fig. 4). A
retrospective study byWang et al of 36 patients following RFA
or surgical resection of HCC found that PET/CT had a signifi-
cantly higher sensitivity and accuracy (96.7 and 94.4%, re-
spectively) compared with contrast-enhanced US (56.7 and
63.9%, respectively).21 Similarly, Chen et al retrospectively
reviewed 33 lesions treated with RFA in 28 patients, and
reported that PET/CT demonstrated superior sensitivity and
accuracy (94.1 and 87.9%, respectively) compared with MRI
(66.7 and 75%, respectively) and multiphase contrast-en-
hanced CT (66.7 and 64.3%, respectively).22
Detecting local recurrence to allow retreatment and pro-
long survival is the goal of early and frequent postablation
PET/CT. Although no established guidelines exist for when to
perform PET/CT after ablation, intervals of 3 to 6 months for
Figure 2 Axial postcontrast T1-weighted MR image from a study
performed 3 weeks after percutaneous radiofrequency ablation of a
liver lesion demonstrating rim enhancement of the ablated lesion
(arrow) with central necrosis. MR, magnetic resonance.
Figure 3 Axial PET image acquired several hours following radio-
frequency ablation of a liver metastasis demonstrating focal photo-
penia at the ablation site (arrow). PET, positron emission tomography.
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the 1st year following ablation have been proposed due to the
fact that more than 95% of local recurrences are identified
within 1 year of treatment.23 However, one retrospective
study reported no effect by the frequency of surveillance
following ablation or resection of colorectal liver metastases
on the time to a second procedure or median survival
duration.24 This suggests that more research is needed to
create definitive guidelines for PET/CT surveillance following
ablation of hepatic malignancy.
Pulmonary Malignancies
Following percutaneous ablation of pulmonary lesions, high
recurrence rates are observed for primary lung tumors (up to
45%) and metastatic pulmonary lesions (20–30%).7,25 Similar
to hepatic disease, early detection of recurrence is important
to allow for retreatment.
Within the first several days following ablation, central
photopenia at the ablation site with a surrounding rim of
intense FDG uptake is commonly observed.3 Peripheral FDG
uptake corresponding to reactive changes in lung tissue
surrounding the ablation site may be seen as early as 1 day
following ablation and last for up to 6 months.3,26 At 6 to
12 months following ablation, contraction of the peripheral
reactive lung tissue leads to a decrease in the size of the
ablated lesion on CT and increasing FDG activity in the center
of the lesion. These reactive changes may cause the SUV to
remain equal to or greater than the preablation SUV for up to
1 year following ablation, and the pattern of FDG uptake on
PET/CT may identify recurrence better than SUV alone. Sing-
nurkar et al identified six patterns of FDG uptake following
ablation and categorized them as favorable or unfavorable.
Unfavorable patterns, including focal uptake and rim with a
focus of uptake at the site of the original tumor, were
associated with local recurrence. Favorable patterns of up-
take, including diffuse, heterogenous, rim, and rim uptake
with a focus at a location away from the original tumor, were
more likely to represent inflammation. Inflammatory FDG
uptake can also be seen along the path of the ablation probe
and in mediastinal lymph nodes for up to 3 months following
ablation.5
PET/CT follow-up beginning at 3 months postablation of
pulmonary tumors may be optimal to limit false-positive
results due to inflammation.5,27,28 PET/CT has also been
shown to be better at detecting residual or recurrent disease
as compared with CT alone in the 6-month postprocedural
period.29,30
Future Directions
Recently, a method has been described utilizing a split dose of
FDG that allows PET to be used for both intraprocedural lesion
targeting and immediate postprocedural evaluation of abla-
tion completeness.31 An initial 4 mCi of FDG is given intrave-
nously for preprocedural PET imaging. These images are fused
with CT images acquired to localize the lesion of interest,
guide placement of the ablation probes, and confirm the
position of the probe before ablation. Following ablation, an
8 mCi dose of FDG is administered and a follow-up PET/CT is
performed. Because of the higher dose of the second FDG
administration and the decay of the initial dose throughout
the procedure, approximately 90% of the signal on the follow-
up PET is from the second injection. Utilizing this “split-dose”
method, no residual activity was seen in 97% (28/29) of
lesions. The lesion with residual activity was immediately
retreated and demonstrated no evidence of recurrence on
follow-up imaging. Marginal recurrences occurred in 7%
(2/28) of the lesions negative for residual activity on the
postprocedural PET. Initial results using this technique are
promising, warranting further investigation.
Another possibility for real-time PET imaging during
ablation involves the utilization of 15 O-water as a perfusion
radiotracer. Because of its 2 minutes half-life, PET imaging
can be performed at 20 minutes intervals, demonstrating
areas of tumor that are still taking up water and are,
therefore, still viable. This allows for simultaneous PET-
guided lesion targeting and determination of ablation com-
pleteness.32 However, because of its short half-life, produc-
tion of this isotope requires an onsite cyclotron, greatly
limiting its availability; this procedure has yet to be tested
on humans.
The use of electromagnetic device tracking with multi-
modality preprocedural imaging such as PET or MRI has
been described to provide real-time guidance for the
placement of ablation probes. An ablation probe containing
electromagnetic sensor coils within the tip is tracked
within a patient using technology similar to a global
positioning system, and its location and orientation may
be displayed relative to the preprocedural imaging. Real-
time US can also be fused with CT and PET images, and the
position of the transducer can be tracked with optical or
electromagnetic sensors.33,34
The development of combined PET/MRI over the past
several years has multiple applications with regard to percu-
taneous ablation. With the addition of simultaneous PET
Figure 4 Axial PET image acquired several months after percutaneous
radiofrequency ablation of a colorectal liver metastasis demonstrates
nodular increased FDG uptake adjacent to the photopenic ablation site
(arrow). This finding is compatible with recurrence outside of the
previously ablated region. PET, positron emission tomography.
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imaging to MRI, the increased sensitivity for detecting both
intrahepatic and extrahepatic disease has the potential to
improve the accuracy of cancer staging. In addition, the
technology allows for possible combined PET and MRI guid-
ance during ablation procedures for the purpose of lesion
targeting, and after treatment, the combined imaging modal-
ities could allow for earlier diagnosis and treatment of
residual and recurrent disease.35
Conclusion
PET/CT can be useful in determining the appropriateness of
treating hepatic and pulmonary malignancies by restaging
patients with previously nonvisualized disease. During per-
cutaneous ablation, the addition of PET imaging can help
target lesions that are difficult to see with conventional
imaging. In the follow-up period, PET/CT has proven to be
more sensitive in detecting residual or recurrent disease
compared with conventional imaging for both hepatic and
pulmonary malignancies. There is no consensus as to the
follow-up intervals at which PET/CT should be performed for
surveillance after treatment of hepatic disease, but an initial
3-month follow-up study after ablation of pulmonary disease
has been recommended by multiple authors. Future uses of
PET associated with percutaneous ablation include utilizing
combined PET/MRI before, during, and after treatment, and
utilization of split FDG dosing or alternative radiotracers for
potential real-time targeting with determination of treat-
ment completeness.
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